Association of Electronic Nicotine Delivery System Use With Cigarette Smoking Progression or Reduction Among Young Adults.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
02 11 2020
Historique:
entrez: 24 11 2020
pubmed: 25 11 2020
medline: 20 1 2021
Statut: epublish

Résumé

The prevalence of electronic nicotine delivery systems (ENDS) use, including e-cigarettes, among US young adults (YAs) has raised questions about how these products may affect future tobacco and nicotine use among YAs. Given this prevalence and that young adulthood is a critical period for the establishment of tobacco and nicotine use, it is important to consider the association between ENDS use and cigarette smoking specifically in this age group. To examine whether ENDS use frequency or intensity is associated with changes in cigarette smoking among US YA ever smokers during 1 year. This cohort study used 3 waves of data (2013-2014, 2014-2015, and 2015-2016) from the Population Assessment of Tobacco and Health (PATH) Study, an ongoing longitudinal cohort study of adults and youth. Unweighted 1:6 propensity score matching was used to match participants on wave 1 risk factors for ENDS use at wave 2. The changes in smoking between wave 2 and wave 3 were assessed using the matched sample. In total, 1096 ENDS-naive, ever cigarette-smoking YAs (18-24 years of age) at wave 1 who participated in wave 2 and wave 3 and who had complete data in the PATH Study were included in the analyses, which were conducted from August 2018 to October 2019. Never ENDS use (n = 987), any previous 30-day ENDS use (n = 109), 1 to 5 days of ENDS use in the previous 30 days (n = 75), and 6 or more days ENDS use in the previous 30 days at wave 2 (n = 34). The analytic sample was selected using multiple variables based on peer-reviewed literature supporting associations with ENDS use. The main outcomes-changes in cigarette smoking behavior between wave 2 and wave 3-were defined using 2 measures: (1) change in smoking frequency, defined as the number of smoking days in the previous 30 days at wave 3 vs wave 2, and (2) change in smoking intensity, defined as the number smoking days in the previous 30 days multiplied by the mean number of cigarettes consumed on smoking days at wave 3 vs wave 2. The present cohort analyses included 1096 YA ever smokers who were ENDS naive at wave 1. The majority of the sample were women (609 [55.6%]) and White individuals (698 [63.7%]), and the mean (SD) age was 21.4 (1.9) years. In wave 1, 161 YAs (14.7%) were daily smokers in the previous 30 days. After propensity score matching, no statistically significant associations were observed between any definition of wave 2 ENDS use and changes in either the frequency or intensity of smoking at wave 3. In this cohort study of US YA ever smokers, ENDS use was not associated with either decreased or increased cigarette smoking during a 1-year period. However, it is possible that the rapidly evolving marketplace of vaping products may lead to different trajectories of YA cigarette and ENDS use in the future.

Identifiants

pubmed: 33231634
pii: 2773394
doi: 10.1001/jamanetworkopen.2020.15893
pmc: PMC7686868
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2015893

Commentaires et corrections

Type : CommentIn

Références

Tob Control. 2020 Mar 10;:
pubmed: 32156694
JAMA. 2018 Oct 2;320(13):1379-1380
pubmed: 30285167
JAMA Pediatr. 2017 Aug 1;171(8):788-797
pubmed: 28654986
Stat Med. 2005 May 30;24(10):1563-78
pubmed: 15706581
Ann Intern Med. 2007 Oct 16;147(8):573-7
pubmed: 17938396
Tob Control. 2019 Nov;28(6):676-677
pubmed: 30194085
Tob Control. 2017 Jul;26(4):371-378
pubmed: 27507901
Nicotine Tob Res. 2019 Sep 19;21(10):1320-1330
pubmed: 29788314
Tob Control. 2017 Dec;26(e2):e117-e126
pubmed: 28624763
Stat Med. 2005 Apr 15;24(7):993-1007
pubmed: 15570623
J Natl Cancer Inst. 2019 Oct 1;111(10):1088-1096
pubmed: 30689915
Tob Control. 2020 May;29(Suppl 3):s147-s154
pubmed: 32321848
Tob Control. 2019 Mar;28(2):146-151
pubmed: 29853561
J Clin Epidemiol. 2001 Apr;54(4):387-98
pubmed: 11297888
Tob Control. 2005 Jun;14(3):181-5
pubmed: 15923468
Addict Behav. 2015 Feb;41:142-7
pubmed: 25452058

Auteurs

Jennifer L Pearson (JL)

Division of Social and Behavioral Science/Health Administration and Policy, School of Community Health Sciences, University of Nevada, Reno.
Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Eva Sharma (E)

Westat, Rockville, Maryland.

Ning Rui (N)

Westat, Rockville, Maryland.

Michael J Halenar (MJ)

Westat, Rockville, Maryland.

Amanda L Johnson (AL)

Office of Science, Center for Tobacco Products Food and Drug Administration, Silver Spring, Maryland.

K Michael Cummings (KM)

Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston.

Hoda T Hammad (HT)

Office of Science, Center for Tobacco Products Food and Drug Administration, Silver Spring, Maryland.

Annette R Kaufman (AR)

Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Cindy Tworek (C)

Office of Science, Center for Tobacco Products Food and Drug Administration, Silver Spring, Maryland.

Maciej L Goniewicz (ML)

Division of Cancer Prevention and Population Sciences, Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Heather L Kimmel (HL)

Division of Epidemiology, Services, and Prevention Research, National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.

Susanne Tanski (S)

Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.

Wilson M Compton (WM)

National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.

Hannah Day (H)

Office of Science, Center for Tobacco Products Food and Drug Administration, Silver Spring, Maryland.

Bridget K Ambrose (BK)

Office of Science, Center for Tobacco Products Food and Drug Administration, Silver Spring, Maryland.

Maansi Bansal-Travers (M)

Division of Cancer Prevention and Population Sciences, Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Marushka L Silveira (ML)

Division of Epidemiology, Services, and Prevention Research, National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.
Kelly Government Solutions, Rockville, Maryland.

David Abrams (D)

Department of Social and Behavioral Sciences, NYU College of Global Public Health, New York University, New York.

Jeannie Limpert (J)

Office of Science, Center for Tobacco Products Food and Drug Administration, Silver Spring, Maryland.

Mark J Travers (MJ)

Division of Cancer Prevention and Population Sciences, Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Nicolette Borek (N)

Office of Science, Center for Tobacco Products Food and Drug Administration, Silver Spring, Maryland.

Andrew J Hyland (AJ)

Division of Cancer Prevention and Population Sciences, Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Cassandra A Stanton (CA)

Westat, Rockville, Maryland.
Department of Oncology, Georgetown University Medical Center, Washington, DC.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH